Compugen Ltd. Form 6-K Summary
Business Context and Reporting Period
Compugen Ltd., a foreign private issuer based in Holon, Israel, filed this Form 6-K on November 10, 2025. The filing serves to report the Company's third quarter 2025 financial results, which were previously announced via a press release dated November 10, 2025 (Exhibit 99.1).
Key Financial Metrics
The provided filing text acts as a cover document and does not contain specific numerical data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing states that the detailed results are contained within the referenced press release.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed in the text of this Form 6-K. The document solely references the existence of the third quarter 2025 results report.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, risk factors, or details on contingencies. It notes that information from the press release is incorporated by reference into the Company's Registration Statement on Form F-3, except for quotes attributable to Eran Ophir, Ph.D.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 10, 2025) for actual Q3 2025 financial figures.
- Verify the specific revenue and net loss figures reported in the press release.
- Check the press release for any updates on clinical trial progress or partnership milestones.
- Confirm cash position and burn rate details not included in this summary filing.